<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONRC-12002929</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2012-12-05</date_registration>
      <primary_sponsor>The 105th Hospital of PLA</primary_sponsor>
      <public_title>Safety and efficacy study of umbilical cord mesenchymal stem cells transplantation for the treatment of cerebral infarction</public_title>
      <acronym />
      <scientific_title>Safety and efficacy study of umbilical cord mesenchymal stem cells transplantation for the treatment of cerebral infarction</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2009-09-27</date_enrolment>
      <type_enrolment />
      <target_size>Lumbar puncture stem cells therapy:75;Control:50;Vein group:75;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6626</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>cerebral infarction</hc_freetext>
      <i_freetext>Lumbar puncture stem cells therapy:Infusion of  umbilical cord mesenchymal stem cells;Control:Using conventional drug therapy, including the application of cerebral protection agent (such as cell two choline and intravenous infusion of 10 d/course), improve microcirculation (Salvia miltiorrhiza injection and intravenous infusion of 10 d/course), antiplatelet drugs (aspirin 100 mg/d ), statins (simvastatin for 40 mg\d ).  ;Vein group:Infusion of umbilical cord mesenchymal stem cells;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Hongjuan Liu</firstname>
        <middlename />
        <lastname />
        <address>424 Changjiang Road West, Heifei, Anhui, China</address>
        <city />
        <country1 />
        <zip>230031</zip>
        <telephone>+86 13965053597</telephone>
        <email>liuhongjuan105@yahoo.cn</email>
        <affiliation>Department of Neurology,The 105th Hospital of PLA</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Qingsong Wang</firstname>
        <middlename />
        <lastname />
        <address>424 Changjiang Road West, Heifei, Anhui, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18909696277</telephone>
        <email>wangqs65@yahoo.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Individuals aged 18â€“80 years of both sexes were eligible for the study if they had the following characteristics:
1. Ischemic stroke in the middle cerebral artery (MCA) territory evidenced by computed tomography or MRI occurring within 14 days;
2. Recanalization of the involved MCA as assessed by transcranial Doppler studies or by magnetic resonance angiography;
3. A score between four and 17 according to the National Institutes of Health Stroke Scale (NIHSS).</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>80</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Ipsilateral carotid stenosis (&gt;50%,by Doppler studies);
2. Neurological worsening (&gt;four points in the NIHSS) before injection due to either edema or intracerebral hemorrhage;
3. Thrombophilias or primary hematological diseases;
4. Previous stroke with modifed Rankin Scale(mRS) of more than 2;
5. Neurodegenerative disorders;
6. Autoimmune disorders;
7. Intracardiac thrombus;
8. Sepsis;
9. History of neoplasia or other comorbidity that could impact a patients short-term survival;
10. renal failure (serum creatinine &gt;2 mg/ml);
11. Pregnancy or previous participation in other clinical trials;
12. Diffculty in obtaining vascular access for percutaneous procedure;
13. Liver failure;(14)Lacunar stroke;(15)Any condition that in the judgment of the investigator would place the patient under undue risk.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>NIHSS-Score;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Discipline supporting program funding from the 105th Hospital of PLA</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-12-12</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>